Publicaciones (123) Publicaciones de Jose Luis Fuster Soler

2024

  1. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma

    Journal of Neuro-Oncology, Vol. 166, Núm. 3, pp. 407-415

  2. Chromosomal instability in aneuploid acute lymphoblastic leukemia associates with disease progression

    EMBO molecular medicine, Vol. 16, Núm. 1, pp. 64-92

  3. Clonal heterogeneity and genomic evolution in intrachromosomal amplification of chromosome 21: A case report

    British Journal of Haematology

  4. Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Journal of Neuro-Oncology, (2024), 166, 3, (407-415), 10.1007/s11060-023-04513-1)

    Journal of Neuro-Oncology

  5. ECLIM-SEHOP: how to develop a platform to conduct academic trials for childhood cancer

    Clinical and Translational Oncology, Vol. 26, Núm. 9, pp. 2351-2359

  6. Genetic and phenotypic findings in 34 novel Spanish patients with DDX3X neurodevelopmental disorder

    Clinical Genetics, Vol. 105, Núm. 2, pp. 140-149

  7. Haploidentical versus Cord Blood Transplantation in Pediatric AML. A Retrospective Outcome Analysis on Behalf of the Pediatric Subcommittee of GETH (Grupo Español de Trasplante Hematopoyético)

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1015.e1-1015.e13

  8. Hematopoietic stem cell transplantation in children with chronic granulomatous disease: the Spanish experience

    Frontiers in Immunology, Vol. 15

  9. Identification of copy-number variants in patients with overgrowth disorders

    Clinical Genetics, Vol. 106, Núm. 5, pp. 614-624

  10. Integrative single-cell expression and functional studies unravels a sensitization to cytarabine-based chemotherapy through HIF pathway inhibition in AML leukemia stem cells

    HemaSphere, Vol. 8, Núm. 2

  11. Measurable residual disease study through three different methods can anticipate relapse and guide early interventions in childhood acute lymphoblastic leukemia

    Clinical and Translational Oncology, Vol. 26, Núm. 1, pp. 278-287

2023

  1. Haploidentical Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acquired Hypocellular Bone Marrow Failure

    Transplantation and Cellular Therapy, Vol. 29, Núm. 10, pp. 621.e1-621.e6

  2. Haploidentical vs. HLA-matched donor hematopoietic stem-cell transplantation for pediatric patients with acute lymphoblastic leukemia in second remission: A collaborative retrospective study of the Spanish Group for Bone Marrow Transplantation in Children (GETMON/GETH) and the Spanish Childhood Relapsed ALL Board (ReALLNet)

    Frontiers in Pediatrics, Vol. 11

  3. Looking Towards 2030: Strengthening the Environmental Health in Childhood–Adolescent Cancer Survivor Programs

    International Journal of Environmental Research and Public Health, Vol. 20, Núm. 1

  4. Measurable residual disease study through three different methods can anticipate relapse and guide pre-emptive therapy in childhood acute myeloid leukemia

    Clinical and Translational Oncology, Vol. 25, Núm. 5, pp. 1446-1454

  5. TIM3, a human acute myeloid leukemia stem cell marker, does not enrich for leukemia-initiating stem cells in B-cell acute lymphoblastic leukemia

    Haematologica

  6. The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP)

    Frontiers in Pediatrics, Vol. 11

  7. Treosulfan-Based Conditioning Regimen In Pediatric Hematopoietic Stem Cell Transplantation: A Retrospective Analysis on Behalf of the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC)

    Transplantation and Cellular Therapy, Vol. 29, Núm. 11, pp. 702.e1-702.e11

2022

  1. A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL

    Molecular Therapy, Vol. 30, Núm. 2, pp. 550-563

  2. Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high-hyperdiploid B-cell acute lymphoblastic leukemia

    Molecular Oncology, Vol. 16, Núm. 16, pp. 2899-2919